For the past 80 years, plasma-derived therapeutics have been manufactured through a process known as “cold ethanol fractionation.” Through this process, plasma proteins are extracted from human plasma that are then used as life-saving therapeutics.
But now, the future of manufacturing is evolving.
Evolve is opening our first commercial manufacturing facility, located in Sachse, Texas, in 2024. The state-of-the-art facility will be the first globally to use our proprietary PlasmaCap® EBA technology to extract more of the precious proteins present in each liter of donor plasma, for efficient, sustainable, commercial-scale production of critical plasma-derived therapeutics.
We’re committed to advancing the way biologics are manufactured, and we’re using our innovative technology to improve lives for patients around the world.
Our first commercial manufacturing facility will enable us to sustainably and efficiently serve the growing demand for critical plasma proteins—and the patients who need these therapeutics.
We’ve planned for the initial processing capacity of one million liters of plasma annually, with eventual expansion to two million liters.
Stay tuned for more project details coming very soon.
Creating up to
for transportation & workforce
for commercial production
Groundbreaking ceremony held following purchase of land parcel
Construction of the Commercial Facility
Realizing our vision
We’re ready to hear from you. Interested in media inquiries, careers, or more? Select from the dropdown menu and your form will reach the people you want to contact.
At Evolve, we believe in talent. Our firm is dedicated to one thing: developing lifesaving plasma-derived therapeutics from our patented PlasmaCap EBA technology. If you want to join us, look at open positions on our Careers page. We are glad to become part of Sachse, TX, and to be creating hundreds of jobs in our new community.